|
|
Post by mnkdfann on Aug 11, 2017 22:32:20 GMT -5
Maxim Sees Over 200% Upside for MannKind Corporation (MNKD) Jason Cohen, Editor-August 11, 2017, 2:59 PM EDT SHARE ON: Shares of MannKind Corporation (NASDAQ:MNKD) are up nearly 3% in Friday trading session, as the inhaled insulin drug maker gets a vote of confidence from Maxim analyst Jason Kolbert. The analyst initiated coverage on MNKD with a Buy rating and price target of $4.00, which represents a potential upside of 245% from where the stock is currently trading. (To watch Kolber’s track record, click here) It's just too bad that the original article included a link to his track record.  |
|
|
|
Post by sportsrancho on Aug 12, 2017 4:18:45 GMT -5
Maxim Sees Over 200% Upside for MannKind Corporation (MNKD) Jason Cohen, Editor-August 11, 2017, 2:59 PM EDT SHARE ON: Shares of MannKind Corporation (NASDAQ:MNKD) are up nearly 3% in Friday trading session, as the inhaled insulin drug maker gets a vote of confidence from Maxim analyst Jason Kolbert. The analyst initiated coverage on MNKD with a Buy rating and price target of $4.00, which represents a potential upside of 245% from where the stock is currently trading. (To watch Kolber’s track record, click here) It's just too bad that the original article included a link to his track record. Post if you can. I haven't been able to get to the articles so have had to copy off ST. |
|
|
|
Post by mnkdfann on Aug 12, 2017 8:40:20 GMT -5
|
|
|
|
Post by morfu on Aug 13, 2017 18:15:26 GMT -5
"Afrezza could shift the paradigm in diabetes management and with Afrezza now in the hands of a very capable management team, the focus is on execution. In the U.S., a conservative 5% share of the insulin market is a $350M opportunity. At the current ~$120M market capitalization there is significant upside, in our view." I seem to misunderstand something here.. This guy seems to think that Afrezza can win a 5% of the insulin market and concludes a 4$ share price from that!? If Mannkind gets a 350M$/year share of the American insulin market, that would actually represent almost 4$ earning per share! The 4$ share value seems heavily at odds with these assumptions!? In any case, what is the typical time window of when his price target would be achieved!? Is that the current value of the company in hos opinion without any news!? So any time we gain a lets say 5% increase in script counts that price target would move accordingly or how does that work!? Read more: mnkd.proboards.com/thread/8371/maxim-group-starts-mnkd-buy?page=4#ixzz4pgET5aqP |
|
|
|
Post by sportsrancho on Aug 13, 2017 19:03:14 GMT -5
"Afrezza could shift the paradigm in diabetes management and with Afrezza now in the hands of a very capable management team, the focus is on execution. In the U.S., a conservative 5% share of the insulin market is a $350M opportunity. At the current ~$120M market capitalization there is significant upside, in our view." I seem to misunderstand something here.. This guy seems to think that Afrezza can win a 5% of the insulin market and concludes a 4$ share price from that!? If Mannkind gets a 350M$/year share of the American insulin market, that would actually represent almost 4$ earning per share! The 4$ share value seems heavily at odds with these assumptions!? In any case, what is the typical time window of when his price target would be achieved!? Is that the current value of the company in hos opinion without any news!? So any time we gain a lets say 5% increase in script counts that price target would move accordingly or how does that work!? Read more: mnkd.proboards.com/thread/8371/maxim-group-starts-mnkd-buy?page=4#ixzz4pgET5aqP Yes I thought the same thing. Price targets are anytime from now to a year. But depending on what happens they move them up or down anytime. He's being very conservative. Poor guy has taken a lot of crap for this call. But it may be the one that puts him on the map:-) |
|
|
|
Post by centralcoastinvestor on Aug 13, 2017 19:43:19 GMT -5
"Afrezza could shift the paradigm in diabetes management and with Afrezza now in the hands of a very capable management team, the focus is on execution. In the U.S., a conservative 5% share of the insulin market is a $350M opportunity. At the current ~$120M market capitalization there is significant upside, in our view." I seem to misunderstand something here.. This guy seems to think that Afrezza can win a 5% of the insulin market and concludes a 4$ share price from that!? If Mannkind gets a 350M$/year share of the American insulin market, that would actually represent almost 4$ earning per share! The 4$ share value seems heavily at odds with these assumptions!? In any case, what is the typical time window of when his price target would be achieved!? Is that the current value of the company in hos opinion without any news!? So any time we gain a lets say 5% increase in script counts that price target would move accordingly or how does that work!? Read more: mnkd.proboards.com/thread/8371/maxim-group-starts-mnkd-buy?page=4#ixzz4pgET5aqP Yes I thought the same thing. Price targets are anytime from now to a year. But depending on what happens they move them up or down anytime. He's being very conservative. Poor guy has taken a lot of crap for this call. But it may be the one that puts him on the map:-) We all wear that badge of honor. Taking tons of crap for believing in Al Mann's vision. I make no apologies for believing that Afrezza will change diabetes treatment forever. Welcome to the club Maxim! |
|
|
|
Post by morfu on Aug 15, 2017 20:17:57 GMT -5
While I admire your believe, I really would like to know if there is any meat to that prediction, beside the product might skyrocket, so we assume its worth 4$ now or within the next year.. why 4 and not 3.5 or 18$?
|
|
|
|
Post by dreamboatcruise on Aug 15, 2017 20:35:22 GMT -5
While I admire your believe, I really would like to know if there is any meat to that prediction, beside the product might skyrocket, so we assume its worth 4$ now or within the next year.. why 4 and not 3.5 or 18$? They based it on a pretty modest market share, then discounted for time and further discounted because of execution risk. So they at least presented a methodology, which I think you can find online. I suspect they backed into it a bit... wanting to make a strong bullish call from here but not something that would seem outlandish if someone didn't know anything about the market... and give them room to increase later rather than risk decreasing. (the latter is assuming that things go well, finances are resolved and scripts start a sharper trajectory... under those assumptions even this "cautionary" lizard would put a meaningfully higher target than $4) |
|
